Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients

被引:18
作者
Blank, S. [1 ]
Stange, A. [2 ]
Sisic, L. [1 ]
Roth, W. [3 ]
Grenacher, L. [4 ]
Sterzing, F. [5 ]
Burian, M. [1 ]
Jaeger, D. [2 ]
Buechler, M. [1 ]
Ott, K. [1 ]
机构
[1] Univ Heidelberg Hosp, Dept Surg, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany
[3] Heidelberg Univ, Inst Pathol, Heidelberg, Germany
[4] Heidelberg Univ, Dept Diagnost & Intervent Radiol, Heidelberg, Germany
[5] Heidelberg Univ, Dept Radiat Oncol & Radiat Therapy, Heidelberg, Germany
关键词
Esophagogastric cancer; Nonresponder; Prognosis; Morbidity; Mortality; HISTOPATHOLOGICAL TUMOR-REGRESSION; SQUAMOUS-CELL CARCINOMA; ESOPHAGEAL CANCER; NEOADJUVANT CHEMOTHERAPY; PERIOPERATIVE CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; GASTRIC-CANCER; RECTAL-CANCER; SURGERY; TRIAL;
D O I
10.1007/s00423-012-1034-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Preoperative treatment is nowadays standard for locally advanced esophagogastric cancer in Europe. Surprisingly, little attention has been paid to nonresponders so far. The aim of our retrospective exploratory study was the comparison of responder, nonresponder, and primary resected patients in respect of outcome considering the tumor entity. From 2001-2011, 607 patients with locally advanced esophagogastric carcinoma (adenocarcinoma of the esophagogastric junction (AEG), n = 293; squamous cell cancer (SCC), n = 111; gastric cancer, n = 203) after preoperative treatment (n = 281) or primary resection (n = 326) were included. Histopathological response evaluation (Becker criteria) was available for 263. A total of 76/263 (28.9 %) were responders (< 10 % residual tumor). There was an association of response with increased R0 resections (p < 0.001) but also with a higher complication rate (p = 0.008) compared to nonresponse and primary surgery. Mortality was not influenced. Increased R0 resections after response were confirmed in every tumor entity (AEG, p = 0.010; SCC, p = 0.023; gastric cancer, p = 0.006). Median survival was best for responders with 43.5 months [95 % confidence interval (CI), 27.9-59.1], followed by nonresponders with 24.3 months (95 % CI, 21.6-27.0) and primary resected patients with 20.8 months (95 % CI, 17.7-23.9; p = 0.002). AEG (p = 0.012) and gastric cancer (p = 0.017) revealed identical results, but in the subgroup of SCC, the survival of nonresponders (median, 11.6 months; 95 % CI, 6.9-16.3) was even worse than for primary resected patients (median, 23.8 months; 95 % CI, 1.7-46.0; p = 0.012). The histopathological response rate was low. Generally, nonresponding patients with AEG or gastric cancer seem not to have a disadvantage compared to primary resected patients, but nonresponders with SCC have a worse prognosis, which strengthens the demand for a critical patient selection in surgery for this tumor entity.
引用
收藏
页码:211 / 220
页数:10
相关论文
共 31 条
[21]   Adenocarcinomas of the Esophagogastric Junction Are More Likely to Respond to Preoperative Chemotherapy than Distal Gastric Cancer [J].
Reim, Daniel ;
Gertler, Ralf ;
Novotny, Alexander ;
Becker, Karen ;
zum Bueschenfelde, Christian Meyer ;
Ebert, Matthias ;
Dobritz, Martin ;
Langer, Rupert ;
Hoefler, Heinz ;
Friess, Helmut ;
Schumacher, Christoph .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (07) :2108-2118
[22]   The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma [J].
Rizk, NP ;
Bach, PB ;
Schrag, D ;
Bains, MS ;
Turnbull, AD ;
Karpeh, M ;
Brennan, MF ;
Rusch, VW .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (01) :42-50
[23]   Anastomotic leakage after esophagectomy for cancer: A mortality-free experience [J].
Sarela, Abeezar I. ;
Tolan, Damian J. ;
Harris, Keith ;
Dexter, Simon P. ;
Sue-Ling, Henry M. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2008, 206 (03) :516-523
[24]   Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer - implications for response classification [J].
Schneider, PM ;
Baldus, SE ;
Metzger, R ;
Kocher, M ;
Bongartz, R ;
Bollschweiler, E ;
Schaefer, H ;
Thiele, J ;
Dienes, HP ;
Mueller, RP ;
Hoelscher, AH .
ANNALS OF SURGERY, 2005, 242 (05) :684-692
[25]   Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954 [J].
Schuhmacher, Christoph ;
Gretschel, Stephan ;
Lordick, Florian ;
Reichardt, Peter ;
Hohenberger, Werner ;
Eisenberger, Claus F. ;
Haag, Cornelie ;
Mauer, Murielle E. ;
Hasan, Baktiar ;
Welch, John ;
Ott, Katja ;
Hoelscher, Arnulf ;
Schneider, Paul M. ;
Bechstein, Wolf ;
Wilke, Hans ;
Lutz, Manfred P. ;
Nordlinger, Bernard ;
Van Cutsem, Eric ;
Siewert, Joerg R. ;
Schlag, Peter M. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (35) :5210-5218
[26]   Are squamous and adenocarcinomas of the esophagus the same disease? [J].
Siewert, J. Ruediger ;
Ott, Katja .
SEMINARS IN RADIATION ONCOLOGY, 2007, 17 (01) :38-44
[27]   Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis [J].
Sjoquist, Katrin M. ;
Burmeister, Bryan H. ;
Smithers, B. Mark ;
Zalcberg, John R. ;
Simes, R. John ;
Barbour, Andrew ;
Gebski, Val .
LANCET ONCOLOGY, 2011, 12 (07) :681-692
[28]   Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus [J].
Stahl, M ;
Stuschke, M ;
Lehmann, N ;
Meyer, HJ ;
Walz, MK ;
Seeber, S ;
Klump, B ;
Budach, W ;
Teichmann, R ;
Schmitt, M ;
Schmitt, G ;
Franke, C ;
Wilke, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2310-2317
[29]   Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer [J].
Wichmann, MW ;
Müller, C ;
Meyer, G ;
Strauss, T ;
Hornung, HM ;
Lau-Werner, U ;
Angele, MK ;
Schildberg, FW .
ARCHIVES OF SURGERY, 2002, 137 (02) :206-210
[30]  
Yamaguchi Y, 2006, ONCOL REP, V15, P895